Ivantis Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Ivantis's estimated annual revenue is currently $18.6M per year.
- Ivantis received $25.0M in venture funding in January 2017.
- Ivantis's estimated revenue per employee is $251,000
- Ivantis's total funding is $113.6M.
- Ivantis has 74 Employees.
- Ivantis grew their employee count by 40% last year.
- Ivantis currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
|i-CAT 3D CBCT I...||$4.3M||17||N/A||N/A||2.5/5||N/A|
What Is Ivantis?
Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
There are four FDA-approved MIGS stents: the Glaukos's iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. That number could ...
Ivantis today released two-year results from a study comparing its Hydrus Microstent to Glaukos' (NYSE:GKOS) iStent trabecular micro-bypass ...
A study accepted for publication in the journal Ophthalmology could give Ivantis a competitive advantage against one of the top players in the ...
|2013-02-04||$27.0M||B||Ascension Health Ventures||Article|
|2013-08-21||$5.0M||B||EDBI of Singapore||Article|
|2017-01-10||$25.0M||C||RA Capital Management||Article|